1
|
Zagorodko O, Arroyo-Crespo JJ, Nebot VJ, Vicent MJ. Polypeptide-Based Conjugates as Therapeutics: Opportunities and Challenges. Macromol Biosci 2016; 17. [DOI: 10.1002/mabi.201600316] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Revised: 09/02/2016] [Indexed: 12/16/2022]
Affiliation(s)
- Oleksandr Zagorodko
- Polymer Therapeutics Laboratory; Centro de Investigación Príncipe Felipe; Valencia 46012 Spain
| | - Juan José Arroyo-Crespo
- Polymer Therapeutics Laboratory; Centro de Investigación Príncipe Felipe; Valencia 46012 Spain
| | - Vicent J. Nebot
- Polymer Therapeutics Laboratory; Centro de Investigación Príncipe Felipe; Valencia 46012 Spain
- Polypeptide Therapeutic Solutions SL; Centro de Investigación Príncipe Felipe; Valencia 46012 Spain
| | - María J. Vicent
- Polymer Therapeutics Laboratory; Centro de Investigación Príncipe Felipe; Valencia 46012 Spain
| |
Collapse
|
2
|
|
3
|
Sanchis J, Canal F, Lucas R, Vicent MJ. Polymer–drug conjugates for novel molecular targets. Nanomedicine (Lond) 2010; 5:915-35. [DOI: 10.2217/nnm.10.71] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Polymer therapeutics can be already considered as a promising field in the human healthcare context. The discovery of the enhanced permeability and retention effect by Maeda, together with the modular model for the polymer–drug conjugate proposed by Ringsdorf, directed the early steps of polymer therapeutics towards cancer therapy. Orthodox anticancer drugs were preferentially chosen in the development of the first conjugates. The fast evolution of polymer chemistry and bioconjugation techniques, and a deeper understanding of cell biology has opened up exciting new challenges and opportunities. Four main directions have to be considered to develop this ‘platform technology’ further: the control of the synthetic process, the exhaustive characterization of the conjugate architectures, the conquest of combination therapy and the disclosure of new therapeutic targets. We illustrate in this article the exciting approaches offered by polymer–drug conjugates beyond classical cancer therapy, focusing on new, more effective and selective targets in cancer and in their use as treatments for other major human diseases.
Collapse
Affiliation(s)
| | | | - Rut Lucas
- Polymer Therapeutics Laboratory, Medicinal Chemistry Department, Centro de Investigación Príncipe Felipe. Av. Autopista del Saler, 16. E-46012 Valencia, Spain
| | - María J Vicent
- Polymer Therapeutics Laboratory, Medicinal Chemistry Department, Centro de Investigación Príncipe Felipe. Av. Autopista del Saler, 16. E-46012 Valencia, Spain
| |
Collapse
|